Please assess the completion status of the following clinical trial:

Trial Title: Multimodal Pain Management Following Primary TKA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 40 Years Old~* Scheduled for Primary Total Knee Arthroplasty~Exclusion Criteria:~* Opiate Tolerant (≥60mg/day oral morphine/equivalent for ≥1 week)~* Neuromuscular deficit affecting the lower limbs~  * Peripheral neuropathy~ * Radiculopathy/Sciatica~* Known allergy or intolerance to Bupivacaine or Ropivacaine~* Hepatic Disease~* Renal Disease/Patients needing Dialysis~* Planned unicompartmental knee replacement~* Less than 90 degree of knee flexion preoperatively.~* Patients who lack the capacity to consent or are unwilling to do so~* At the discretion of the PI, patients who may have difficulty complying with standard of care (SOC) followup may also be excluded

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- liposomal bupivacaine (LB) (Exparel) (Type: ACTIVE_COMPARATOR): Mixture of 50 milliliters (mL) of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.
- Ropivacaine cocktail (PIC) (Type: ACTIVE_COMPARATOR): 400 milligrams (mg) Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution
- continuous femoral nerve blocks (cFNB) (Type: ACTIVE_COMPARATOR): Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.~Sciatic nerve block - 0.125% bupivacaine

Based on this trial design, predict the completion outcome and termination type (if applicable).